| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.15 | 0.01 |